Drug Trial Radar · NCT02090283
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Last checked: Nov 19, 2026Latest source record: Nov 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
42
Actual
Start
Mar 26, 2014
Primary completion
Sep 14, 2018
Study completion Sep 14, 2018
Sponsor
- Lead sponsor
- Scioderm, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Amicus Therapeutics; Food and Drug Administration (FDA)
- First posted
- Mar 18, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to assess the continued safety of topical use of SD-101 cream (6%) in participants with Epidermolysis Bullosa (EB). Funding Source: FDA Office of Orphan Products Development
Conditions
- Epidermolysis Bullosa
Interventions
SD-101 dermal cream (6%)Drug
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From baseline to 30 days after last application of study drug (up to a maximum of 54 months)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Palo Alto, California
Site not named
Chicago, Illinois
Site not named
St Louis, Missouri
Site not named
Hackensack, New Jersey
Site not named
Chapel Hill, North Carolina
Site not named
San Antonio, Texas
Site not named
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.